Skip to content

Covering China's BioPharma industry

Covering China's BioPharma industry

Home
Disease Areas
- Oncology
- Immunology
- Autoimmune
- I&I
- Metabolic
- Respiratory
- Cardiovascular
- Ophthalmology
- Neurology
- Rare Diseases
Clinical Trials
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- IIT
Financing
Manufacturing
Regulatory
- FTD
- BTD
- IND
- NDA/BLA
- Approvals
Deals
- M&A
- Partnerships
Events
Companies

Home
Disease Areas
- Oncology
- Immunology
- Autoimmune
- I&I
- Metabolic
- Respiratory
- Cardiovascular
- Ophthalmology
- Neurology
- Rare Diseases
Clinical Trials
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- IIT
Financing
Manufacturing
Regulatory
- FTD
- BTD
- IND
- NDA/BLA
- Approvals
Deals
- M&A
- Partnerships
Events
Companies

Close

Search

Covering China's BioPharma industry

Covering China's BioPharma industry

Home
Disease Areas
- Oncology
- Immunology
- Autoimmune
- I&I
- Metabolic
- Respiratory
- Cardiovascular
- Ophthalmology
- Neurology
- Rare Diseases
Clinical Trials
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- IIT
Financing
Manufacturing
Regulatory
- FTD
- BTD
- IND
- NDA/BLA
- Approvals
Deals
- M&A
- Partnerships
Events
Companies

Home
Disease Areas
- Oncology
- Immunology
- Autoimmune
- I&I
- Metabolic
- Respiratory
- Cardiovascular
- Ophthalmology
- Neurology
- Rare Diseases
Clinical Trials
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- IIT
Financing
Manufacturing
Regulatory
- FTD
- BTD
- IND
- NDA/BLA
- Approvals
Deals
- M&A
- Partnerships
Events
Companies

Close

Search

Browse Tag

Respiratory Diseases

1 Article

Chia Tai Tianqing Pharma (CTTQ)

By Henry Tseng

No Comments on Chia Tai Tianqing Pharma (CTTQ)

10 Min Read

Innovating for Life, Creating Greater Health Value

Companies Metabolic Oncology Respiratory

August 30, 2026

Welcome to BioPharmChina, a dedicated news and information portal covering the rapidly evolving biotechnology and biopharmaceutical industry in China.

Get the latest news in China's BioPharma industry delivered straight to your inbox.

Email

I accept the privacy policy

Latest Articles

Medinno Raises More Than RMB 200 Million to Advance Topical Drug for Diabetic Foot Ulcers
BioNTech and OncoC4’s Gotistobart Nearly Doubles Survival in Previously Treated Squamous NSCLC
Novartis Acquires Global Rights to Sironax Brain-Delivery Platform for $125 Million
GSK Returns to Chimagen for Multiple Myeloma T-Cell Engager in Deal Worth Up to $750 Million
Forlong Biotech’s Pre-B Financing Reaches Nearly RMB 200 Million as It Prepares FL115 for Phase 3 Bladder Cancer Trial

Info

Contact

Email
contact@biopharmchina.com

Location
San Francisco, CA, USA

X
Facebook

Copyright 2026 — BioPharmChina. All rights reserved.